- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05796037
An Observational Study of Patients Living With Chronic Neurological Diseases
Study Overview
Status
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Disease Cohort
Inclusion Criteria:
•Adult patients at the time of enrollment with a diagnosis of ADRD, MCI, PD, or MS by select ICD-10 codes in the EHR interface
Exclusion Criteria:
- Death
- Manual removal (sponsor or site request)
- No EHR interface encounter > 3 years
Engaged Cohort
Inclusion Criteria:
- Adult patients diagnosed and managed for these conditions invited to participate
- Ability to provide written informed consent (or have a legally authorized representative to provide informed consent)
- Care partners may be invited to participate in surveys and will provide informed consent.
Exclusion Criteria:
- Patient expressed desire to withdraw consent to complete PROs
- Care partner expressed desire to withdraw consent to complete PROs
- Failure to complete PROs within 24 weeks of initial invitation
- Greater than 24 months lapse of survey completion after baseline surveys completed
- Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
Age Cohort
Inclusion Criteria:
•Adult patients aged 60 and older at time of enrollment
Exclusion Criteria:
- Death
- Manual removal (sponsor or site request)
- No EHR interface encounter > 3 years
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Disease Cohort
Observational
|
Engaged Cohort
Observational
|
Age Cohort
Observational
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To characterize the natural history of disease in patients living with chronic neurological diseases including ADRD, MCI, PD, or MS
Time Frame: 15 Years
|
A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.
Data from retrospective and prospectively collected medical records will be curated and analyzed to characterize disease natural history and current treatment paradigms.
These data may also establish incidence rates of events of special interest.
Collection of prospective medical records for each patient enables the continuation of these analyses longitudinally for changes and progression.
Part of the characterization of disease or living with a chronic disease may also be informed by patient reported outcome (PRO) measures and care partner surveys.
|
15 Years
|
To assess safety and effectiveness of disease treatments and treatments for complications of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for ADRD, MCI, PD, or MS.
Time Frame: 15 Years
|
The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for ADRD, MCI, PD, or MS. Interval disease and medical events may vary depending on the patient's stage and type of disease and extent of co-morbidities. The progression of pre-existing co-morbidities and variances across populations will also be evaluated. The type, dose and duration of disease-specific therapies will be closely followed with a goal of monitoring treatment paradigms and various combination regimens for clinical response and disease stabilization/progression. |
15 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate provider management practices in the treatment of patients living with ADRD, MCI, PD, or MS
Time Frame: 15 Years
|
Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data.
Disease-specific quality measures will be selected and evaluated
|
15 Years
|
To evaluate longitudinal and patient and care partner reported outcomes in patients with ADRD, MCI, PD, or MS, including care partner burden and quality of life.
Time Frame: 15 Years
|
Longitudinal clinical outcomes and disease progression will be assessed.
Self and proxy-reported patient health measures collect information directly from patients or their informants to measure physical, mental, and social health.
These measures can help clinicians better understand how the disease state and/or various treatments affect what patients are able to do and the symptoms they experience beyond what is typically derived and reported in the EHR as part of traditional clinical evaluations.
The information can also be used to help patients make informed decisions about their healthcare and treatment options.
Care partner surveys can help define the prevalence and needs of care partners who provide support and care to people living with ADRD, MCI, PD, and MS.
|
15 Years
|
3. To select and evaluate quality of care measures for patients living with ADRD, MCI, PD, or MS
Time Frame: 15 Years
|
|
15 Years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the screening accuracy of a passive digital marker algorithm for early ADRD detection among several different healthcare institutions EHRs
Time Frame: 15 Years
|
TARGET-NEURO will enroll an Age Cohort of patients aged 60 years and older, who do not carry a diagnosis code for dementia or mild cognitive impairment.
Patients enrolled in this cohort will have their structured and unstructured EHR data routinely screened using the PDM algorithm.
31 Over time, the refreshed data among Age Cohort patients will be screened for a newly presenting dementia diagnosis or mild cognitive impairment code that suggests symptomatic disease and compared with the PDM prediction.
Records of those patients will be further evaluated to confirm clinical evidence of disease (positive case) and the patient will continue to be passively followed in the Disease Cohort for outcomes.
This exploratory aim enables further validation of the generalizability of the PDM across more health centers and diverse populations.
|
15 Years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neurocognitive Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Multiple Sclerosis
- Parkinson Disease
- Nervous System Diseases
- Alzheimer Disease
- Cognitive Dysfunction
Other Study ID Numbers
- TARGET-NEURO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States